CamGraPhIC raises £1.6 million for high-speed, low-energy graphene photonics
Portfolio company is to accelerate development of technology for scalable, faster, cheaper and more energy efficient optical transceivers — key for 5G data and telecommunication networks.
Read moreExscientia files for IPO in the United States
Exscientia has become the first company in our portfolio to file for an initial public offering.
Read moreBill & Melinda Gates Foundation in $70 million collaboration with Exscientia
Portfolio company Exscientia has entered a $70 million collaboration with the Bill & Melinda Gates Foundation to develop anti-viral therapeutics against Coronavirus and other viruses with pandemic potential.
Read moreHow AquaInSilico aims to help Cape Verde with water scarcity and marine conservation
Our portfolio company AquaInSilico is a United Nations Development Programme Ocean Innovator, involved in a two-year project called Phos-Value. Watch a short video or attend a webinar (in Portuguese) at 4pm BST on Wednesday 8th September
Read moreAdam Westcott to join Pulsiv as Chief Financial Officer
Pulsiv further strengthens team with appointment of Adam Westcott, who has more than 20 years experience in finance at senior levels in both growth businesses and investment banking.
Read moreDavid Flower joins Nandi Proteins as Chief Executive Officer
The former Managing Director Europe for the Bawd Roon Brewery Company (maker of Singha beer), previously Managing Director Home Baking for Kerry Foods, joins the company at an important time.
Read moreNext steps for Pulsiv, a first for Alusid and more in our latest newsletter
Topps Tiles and Alusid in a world first and Pulsiv chief executive Darrel Kingham’s next steps are among the topics covered. Also featured are the latest developments from Celerum, Fieldwork, AquaInSilico and Exscientia.
Read morePulsiv appoints Darrel Kingham as CEO and completes £1.5 million fundraising
Portfolio company Pulsiv announces significant steps to accelerate development, prepare for scale up and deploy its unique power conversion technology.
Read moreExscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb
Portfolio company Exscientia has entered into a collaboration agreement with Bristol Myers Squibb, with upfront and potential milestones of up to $1.2 billion in addition to tiered royalties.
Read moreThe Vaccine Group appoints Jeremy Salt as Chief Executive Officer
Former Chief Scientific Officer of GALVmed and director of Biologicals R&D for Europe, Africa and Middle East of the world’s largest animal health group Zoetis to lead TVG through next phase of development.
Read more